Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PHAT | US
0.05
0.49%
Healthcare
Biotechnology
31/03/2024
05/07/2024
10.30
10.22
10.55
10.09
Phathom Pharmaceuticals Inc. biopharmaceutical company focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States Europe and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals Inc. was incorporated in 2018 and is headquartered in Florham Park New Jersey.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
54.0%1 month
60.0%3 months
63.6%6 months
88.4%-
-
25.37
-3.16
1.32
-2.20
514.07
-
-206.55M
602.91M
602.91M
-
-3.66K
-
-
-3.49K
29.16
45.97
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.12
Range1M
3.25
Range3M
4.01
Rel. volume
0.48
Price X volume
2.50M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd | URGN | Biotechnology | 15.88 | 653.15M | 5.80% | n/a | -246.69% |
Sage Therapeutics Inc | SAGE | Biotechnology | 10.78 | 648.76M | 1.51% | n/a | 0.47% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 10.52 | 634.63M | -0.57% | n/a | 12.50% |
Humacyte Inc | HUMA | Biotechnology | 5.27 | 627.57M | -7.05% | n/a | 71.00% |
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.74 | 617.30M | -0.39% | n/a | 32.90% |
Savara Inc | SVRA | Biotechnology | 4.43 | 612.18M | 2.31% | n/a | 21.80% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 11.75 | 611.33M | -2.49% | n/a | 0.43% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.67 | 603.69M | 0.60% | n/a | 36.78% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 7.89 | 600.66M | -0.63% | n/a | 545.44% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 12.43 | 597.61M | 2.30% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 26.52 | 294.97M | -4.29% | 17.47 | -562.47% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 12.93 | 209.56M | -2.78% | 8.94 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 44.59 | 128.20M | -4.23% | 7.40 | 89.91% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.20 | -2.43 | Cheaper |
Ent. to Revenue | 514.07 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 25.37 | 22.34 | Par |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 63.60 | 76.52 | Par |
Debt to Equity | -3.16 | 0.51 | Cheaper |
Debt to Assets | 1.32 | 0.24 | Expensive |
Market Cap | 602.91M | 3.77B | Emerging |